Trial Profile
A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Radium 223 chloride (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Therapeutic Use
- Acronyms PEACE III
- 29 Mar 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2024.
- 29 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 24 Dec 2022 Planned number of patients changed from 416 to 560.